Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 232

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 232
---
 Preferred Stock, and net proceeds from sale of common stock and pre-funded warrants of $4,273,000, offset by the cash redemption of Series C Preferred Stock of $395,000 and the payment of offering costs of $174,000. 138 During the nine months ended September 30, 2024, net cash provided by financing activities of $12,241,000 was primarily attributable to the receipt of net proceeds of $6,758,000 from the sale of Series A Preferred Stock, $408,000 from short-term borrowings, net proceeds of $500,000 from the sale of Series B Preferred Stock, net proceeds of $704,000 from the sale of Series C Preferred Stock and net proceeds of $4,139,000 from the sale of common stock under the ELOC, offset by the repayment of short-term borrowings of $300,000.

|                                                      |     | For the Years Ended 
 December 31,        
 2024                |    (Pro forma, 
    Predecessor 
 and Successor) |   |     |   |          2023 
 (Predecessor) |   |     |   | Difference |   |
|:-----------------------------------------------------|:----|:--------------------|---------------:|:--|:----|:--|--------------:|:--|:----|:--|-----------:|:--|
| Net cash used in operating activities                |     | $                   |    (12,915,969 | ) |     | $ |    (5,789,987 | ) |     | $ | (7,125,982 | ) |
| Net cash provided by financing activities:           |     |                     |     13,727,634 |   |     |   |       571,678 |   |     |   | 13,155,956 |   |
| Net increase (decrease) in cash and cash equivalents |     | $                   |        811,665 |   |     | $ |    (5,218,309 | ) |     | $ |  6,029,974 |   |

Net cash used in operating activities Net cash used in operating activities for the year ended December 31, 2024 primarily reflected a net loss of $8.3 million, adjusted for the reconciliation of non-cash items such as a gain on of the settlement of vendor liabilities of $3.3 million, depreciation expense of $0.4 million, stock-based compensation